Brief: Gland Pharma Says Conclusion Of USFDA Inspection At Company’S JNPC Facility, Visakhapatnam
25/02/2025 10:34
Feb 25 (Reuters) - Gland Pharma Ltd GLAD.NS :
* GLAND PHARMA - CONCLUSION OF US FDA INSPECTION AT
COMPANY’S JNPC
FACILITY, VISAKHAPATNAM
* GLAND PHARMA - INSPECTION WAS CONCLUDED WITH THREE FORM
483
OBSERVATIONS
Source text: ID:
Further company coverage: GLAD.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant